Advanced in Macroamylasemia

Dr. Nancy Reau

Hepatology
Rush University Medical Group
1615 N Convent St, Suite 1, 
Bourbonnais, IL 
Offers Telehealth
26 Years of Experience
Advanced in Macroamylasemia
Rush University Medical Group
1615 N Convent St, Suite 1, 
Bourbonnais, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nancy Reau is a Hepatologist in Bourbonnais, Illinois. Dr. Reau has been practicing medicine for over 26 years and is rated as an Advanced provider by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Hepatitis C, Hepatitis, Autoimmune Hepatitis, Cirrhosis, and Liver Transplant.

Her clinical research consists of co-authoring 111 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in IL
Hospital Affiliations
Silver Cross Hospital And Medical Centers
Riverside Medical Center
Rush University Medical Center
Presence St Marys Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

RUSH UNIVERSITY MEDICAL GROUP
1615 N Convent St, Suite 1, Bourbonnais, IL 60914
Other Locations
RUSH UNIVERSITY MEDICAL GROUP
1890 Silver Cross Blvd, Suite 215, New Lenox, IL 60451
RUSH UNIVERSITY MEDICAL GROUP
9200 Calumet Ave, Suite E107, Munster, IN 46321
RUSH UNIVERSITY MEDICAL GROUP
1620 W Harrison St, Chicago, IL 60612
RUSH UNIVERSITY MEDICAL GROUP
1725 W Harrison St, Chicago, IL 60612
RUSH UNIVERSITY MEDICAL GROUP
1700 W Van Buren St, Chicago, IL 60612

Additional Areas of Focus

Dr. Reau has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Other
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network - A Longitudinal, Observational Study.
Enrollment Status: Completed
Publish Date: February 28, 2024
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients With Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)
Enrollment Status: Unknown
Publish Date: August 25, 2023
Intervention Type: Drug
Study Drug: Peginterferon Lambda-1a
Study Phase: Phase 3
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)
Enrollment Status: Completed
Publish Date: September 16, 2019
View 5 Less Clinical Trials

108 Total Publications

Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis.
Health Care Resource Utilization and Costs Associated with US Medicaid Sobriety Restrictions on Direct-Acting Antivirals for Hepatitis C Virus: A Retrospective Claims Database Analysis.
Journal: PharmacoEconomics
Published: March 18, 2025
Similar Doctors
Distinguished in Macroamylasemia
Dr. Sheila Eswaran
Hepatology
Distinguished in Macroamylasemia
Dr. Sheila Eswaran
Hepatology

Rush University Medical Group

520 S Maple Ave, Fl 3, 
Oak Park, IL 
 (48.3 miles away)
708-660-5900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sheila Eswaran is a Hepatologist in Oak Park, Illinois. Dr. Eswaran is rated as a Distinguished provider by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Hepatitis, Hepatitis C, Nonalcoholic Steatohepatitis (NASH), Alcoholic Cirrhosis, and Liver Transplant.

Advanced in Macroamylasemia
Dr. Swati Antala
Hepatology
Advanced in Macroamylasemia
Dr. Swati Antala
Hepatology
225 E Chicago Ave, 
Chicago, IL 
 (51.1 miles away)
312-227-4200
Languages Spoken:
English
See accepted insurances

Swati Antala is a Hepatologist in Chicago, Illinois. Dr. Antala is rated as an Advanced provider by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Macroamylasemia, Wilson Disease, Glycogen Storage Disease Type 3, Liver Failure, and Liver Transplant.

Advanced in Macroamylasemia
Dr. Priti Nuthakki
Hepatology
Advanced in Macroamylasemia
Dr. Priti Nuthakki
Hepatology

Franciscan Physician Network

701 Superior Ave, Suite 2700, 
Munster, IN 
 (31.0 miles away)
219-922-7168
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Priti Nuthakki is a Hepatologist in Munster, Indiana. Dr. Nuthakki has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Macroamylasemia. Her top areas of expertise are Visceromegaly, Enlarged Liver, Cirrhosis, and Alcoholic Cirrhosis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Reau's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile